1. Allogene Therapeutics Reports New Data for Off-the-Shelf CAR-T in Lymphoma; Pancreatic Cancer Breakthrough Discussed
New clinical data from Allogene Therapeutics is bolstering the case for its 'off-the-shelf' CAR-T therapy, a potential paradigm shift in treating B-cell lymphoma. Unlike personalized CAR-T treatments, which are manufactured from a patient's own cells, Allogene's approach uses donor cells, aiming for a ready-made, more ...